The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1011
October 10, 1997
View Complete Issue         Table of Contents 2019 
Ardeparin and Danaparoid for Prevention of Deep Vein Thrombosis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Ardeparin and Danaparoid for Prevention of Deep Vein Thrombosis
October 10, 1997 (Issue: 1011)
Ardeparin sodium (Normiflo - Wyeth-Ayerst), a low-molecular-weight heparin, and danaparoid sodium (Orgaran - Organon), a heparinoid, have been approved by the FDA for prevention of deep vein thrombosis. Without anticoagulation, deep vein thrombosis...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Ardeparin and Danaparoid for Prevention of Deep Vein Thrombosis
Article code: 1011b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.